Heparan Sulfate Proteoglycan-Mediated Entry Pathway for Charged Tri-Platinum Compounds: Differential Cellular Accumulation Mechanisms for Platinum

Department of Chemistry, Virginia Commonwealth University, Richmond, Virginia 23284, United States.
Molecular Pharmaceutics (Impact Factor: 4.79). 04/2012; 9(6):1795-802. DOI: 10.1021/mp300098t
Source: PubMed

ABSTRACT We examined the mechanism of accumulation of charged polynuclear platinum complexes (PPCs) based on analogy of polyarginine interactions with the cell surface heparan sulfate proteoglycan (HSPG) family of protein-linked glycosoaminoglycan polysaccharides (GAGs). GAGS such as heparan sulfate (HS) and chondroitin sulfate (CS) mediate the cellular entry of many charged molecules. Fluorescence microscopy and flow cytometry showed that PPCs, but not the neutral cisplatin or oxaliplatin, blocked the cellular entry of TAMRA-R(9) (a nonarginine peptide, R(9)) coupled to the TAMRA fluorescent label 5-(and 6-)carboxytetramethylrhodamine) in Chinese hamster ovary (CHO), human colon carcinoma (HCT116), and osteosarcoma (SAOS-2) cells. Furthermore, detection of platinum accumulation in wt CHO, mutant CHO-pgsD-677 (lacking HS), and CHO-pgsA (lacking HS/CS) cells confirms that HSPG-mediated interactions are an important mechanism for PPC internalization but not so for uncharged cisplatin and oxaliplatin. Endocytosis inhibitor studies show that macropinocytosis, a mechanism of cell entry for heparan sulfate GAGs and arginine-rich peptides, is important in the cellular accumulation of noncovalent TriplatinNC and, to a lesser degree, the covalently binding BBR3464. Clathrin-mediated endocytosis, however, was not involved in either case. Overall, the results suggest a new proteoglycan-mediated mechanism for cellular accumulation of PPCs not shared by cisplatin or oxaliplatin. The results have significant implications for the rational design of platinum antitumor drugs with distinct biological profiles in comparison to those of the clinically used agents as well as expanding the chemotypes for HS proteoglycan-dependent receptors.

Download full-text


Available from: Heveline Silva, Mar 24, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: a] Maurizio Losacco, [b] and Giovanni Natile [a] Keywords: Bioinorganic chemistry / Medicinal chemistry / Drug design / Drug delivery / Antitumor agents / Platinum / Copper transport proteins Cisplatin, or cis-diamminedichloridoplatinum(II) cis-[PtCl 2 -(NH 3) 2 ], is a platinum-based anticancer drug largely used for the treatment of various types of cancers, including ovarian and colorectal carcinomas, sarcomas, and lymphomas. To-gether with other platinum-based drugs, it triggers malig-nant cell death by binding to nuclear DNA, which appears to be the ultimate target. In addition to passive diffusion ac-ross the cell membrane, other transport mechanisms,
    European Journal of Inorganic Chemistry 05/2013; 2013(15):2701-2711. DOI:10.1002/ejic.201300001 · 2.97 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Simultaneous multi-element imaging using NanoSIMS (nano-scale secondary ion mass spectrometry), exploiting the novel combination of (195)Pt and (15)N in platinum-am(m)ine antitumour drugs, provides information on the internalisation and subcellular localisation of both metal and ligands, and allows identification of ligand exchange.
    Chemical Communications 05/2013; 49(62). DOI:10.1039/c3cc42098a · 6.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The ability to map multiple biomarkers at the same time has far-reaching biomedical and diagnostic applications. Here, a series of biocompatible poly(d,l-lactic-co-glycolic acid) and polyethylene glycol particles for multicolor and multiplexed imaging are reported. More than 30 particle formulations that exhibit distinct emission signatures (ranging from the visible to NIR wavelength region) are designed and synthesized. These particles are encapsulated with combinations of carbocyanine-based fluorophores DiO, Dil, DiD, and DiR, and are characterized as <100 nm in size and brighter than commercial quantum dots. A particle formulation is identified that simultaneously emits fluorescence at three different wavelengths upon a single excitation at 485 nm via sequential and multiple FRET cascade events for multicolor imaging. Three other particles that display maximum fluorescence intensities at 570, 672, or 777 nm for multiplexed imaging are also identified. These particles are individually conjugated with specific (Herceptin or IgG2A11 antibody) or nonspecific (heptaarginine) ligands for targeting and, thus, could be applied to differentiate different cancer cells from a cell mixture according to the expressions of cell-surface human epidermal growth factor receptor 2 and the receptor for advanced glycation endproducts. Using an animal model subcutaneously implanted with the particles, it is further demonstrated that the developed platform could be useful for in vivo multiplexed imaging.
    Small 06/2013; 9(12). DOI:10.1002/smll.201202655 · 8.37 Impact Factor
Show more